Abstract
Longstanding diabetes mellitus targets kidney, retina, and blood vessels, but its impact upon the nervous system is another important source of disability. Diabetic peripheral neuropathy is a serious complication of inadequately treated diabetes leading to sensory loss, intractable neuropathic pain, loss of distal leg muscles, and impairment of balance and gait. Diabetes has been implicated as a cause of brain atrophy, white matter abnormalities, and cognitive impairment and a risk factor for dementia. Recent studies have incriminated advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic nervous system complications. The availability of RAGE knockout mice and a competitive decoy for AGEs, soluble RAGE (sRAGE), has advanced our knowledge of the RAGE-mediated signalling pathways within the nervous system. They also provide hope for a future novel intervention for the prevention of diabetes-associated neurological complications. This review will discuss current knowledge of diabetes- and RAGE-mediated neurodegeneration, involving the distal-most level of epidermal nerve fibers in skin, major peripheral nerve trunks, dorsal root ganglia, spinal cord, and brain.
Keywords: DRG neurons, GAPDH inhibition, diabetic neuropathy, STZ-induced model, hippocampus
Current Molecular Medicine
Title: RAGE, Diabetes, and the Nervous System
Volume: 7 Issue: 8
Author(s): Cory Toth, Jose Martinez and Douglas W. Zochodne
Affiliation:
Keywords: DRG neurons, GAPDH inhibition, diabetic neuropathy, STZ-induced model, hippocampus
Abstract: Longstanding diabetes mellitus targets kidney, retina, and blood vessels, but its impact upon the nervous system is another important source of disability. Diabetic peripheral neuropathy is a serious complication of inadequately treated diabetes leading to sensory loss, intractable neuropathic pain, loss of distal leg muscles, and impairment of balance and gait. Diabetes has been implicated as a cause of brain atrophy, white matter abnormalities, and cognitive impairment and a risk factor for dementia. Recent studies have incriminated advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic nervous system complications. The availability of RAGE knockout mice and a competitive decoy for AGEs, soluble RAGE (sRAGE), has advanced our knowledge of the RAGE-mediated signalling pathways within the nervous system. They also provide hope for a future novel intervention for the prevention of diabetes-associated neurological complications. This review will discuss current knowledge of diabetes- and RAGE-mediated neurodegeneration, involving the distal-most level of epidermal nerve fibers in skin, major peripheral nerve trunks, dorsal root ganglia, spinal cord, and brain.
Export Options
About this article
Cite this article as:
Toth Cory, Martinez Jose and Zochodne W. Douglas, RAGE, Diabetes, and the Nervous System, Current Molecular Medicine 2007; 7 (8) . https://dx.doi.org/10.2174/156652407783220705
DOI https://dx.doi.org/10.2174/156652407783220705 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis
and Potential Use of Herbal Immunomodulators as Imminent
Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Evidence of Redox Unbalance in Post-Acute Ischemic Stroke Patients
Current Neurovascular Research Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Levetiracetam might act as an efficacious drug to attenuate cognitive deficits of Alzheimer’s disease
Current Topics in Medicinal Chemistry Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design Impact of Dietary Fats on Brain Functions
Current Neuropharmacology Intestinal Absorption and Presystemic Elimination of Various Chemical Constituents Present in GBE50 Extract, a Standardized Extract of Ginkgo biloba Leaves
Current Drug Metabolism How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets Association Constants of Pyridine and Piperidine Alkaloids to Amyloid ß Peptide Determined by Electrochemical Impedance Spectroscopy
Current Alzheimer Research Cognition in Non-Demented Diabetic Older Adults
Current Aging Science Calcium Signalling Toolkits in Astrocytes and Spatio-Temporal Progression of Alzheimer's Disease
Current Alzheimer Research Therapeutic Angiogenesis for Peripheral Artery Diseases by Autologous Bone Marrow Cell Transplantation
Current Pharmaceutical Design Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Early and Mild Phases of Primary Progressive Aphasia: A Case Series
Current Aging Science Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets